F. Cvitkovic

1.3k total citations
28 papers, 947 citations indexed

About

F. Cvitkovic is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, F. Cvitkovic has authored 28 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in F. Cvitkovic's work include Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (9 papers) and Colorectal and Anal Carcinomas (6 papers). F. Cvitkovic is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Colorectal Cancer Treatments and Studies (9 papers) and Colorectal and Anal Carcinomas (6 papers). F. Cvitkovic collaborates with scholars based in France, United States and Luxembourg. F. Cvitkovic's co-authors include Éric François, Michel Ducreux, D. Peiffert, X. Mirabel, C. Lemanski, Jean‐François Seitz, Maya Gutierrez, Jean‐Pierre Gérard, Marc Giovannini and Jacques Médioni and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

F. Cvitkovic

27 papers receiving 933 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
F. Cvitkovic France	15	560	426	324	160	139	28	947
Paulus Schurr Germany	13	387 0.7×	325 0.8×	268 0.8×	140 0.9×	54 0.4×	28	807
Maximilian Weniger Germany	16	562 1.0×	440 1.0×	210 0.6×	95 0.6×	157 1.1×	38	982
Takanobu Yamao Japan	15	548 1.0×	377 0.9×	303 0.9×	95 0.6×	117 0.8×	55	840
Michael A. Ströhlein Germany	16	497 0.9×	570 1.3×	169 0.5×	212 1.3×	42 0.3×	24	1.1k
Tie-Hua Rong China	16	289 0.5×	320 0.8×	455 1.4×	41 0.3×	103 0.7×	37	833
Toshihide Imaizumi Japan	16	803 1.4×	542 1.3×	363 1.1×	31 0.2×	301 2.2×	76	1.1k
Bradley A. Krasnick United States	17	500 0.9×	145 0.3×	150 0.5×	133 0.8×	261 1.9×	46	733
Ui Sup Shin South Korea	17	567 1.0×	401 0.9×	145 0.4×	31 0.2×	86 0.6×	38	805
P H de Mulder Netherlands	13	322 0.6×	272 0.6×	145 0.4×	220 1.4×	39 0.3×	18	754
Heike Loeser Germany	17	280 0.5×	266 0.6×	274 0.8×	89 0.6×	70 0.5×	30	731

Countries citing papers authored by F. Cvitkovic

Since Specialization

Citations

This map shows the geographic impact of F. Cvitkovic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Cvitkovic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Cvitkovic more than expected).

Fields of papers citing papers by F. Cvitkovic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Cvitkovic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Cvitkovic. The network helps show where F. Cvitkovic may publish in the future.

Co-authorship network of co-authors of F. Cvitkovic

This figure shows the co-authorship network connecting the top 25 collaborators of F. Cvitkovic. A scholar is included among the top collaborators of F. Cvitkovic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Cvitkovic. F. Cvitkovic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malka, David, Florence Castan, Éric François, et al.. (2015). FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA).. Journal of Clinical Oncology. 33(15_suppl). 4013–4013. 12 indexed citations

Cvitkovic, F. & Emmanuelle Mouret‐Fourme. (2013). Épidémiologie et aspects cliniques des métastases osseuses. Bulletin du Cancer. 100(11). 1073–1081. 4 indexed citations

Trocóniz, Iñaki F., et al.. (2012). Population pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 70(2). 239–250. 18 indexed citations

Cacheux, Wulfran, Astrid Lièvre, Anne de la Rochefordière, et al.. (2012). Chemotherapy in the treatment of anal canal carcinoma. Digestive and Liver Disease. 44(10). 803–811. 4 indexed citations

Gutierrez, Maya, et al.. (2011). Méningites carcinomateuses des cancers du sein surexprimant HER2 : pour un traitement spécifique ?. Bulletin du Cancer. 98(4). 417–424. 6 indexed citations

Malka, David, Valérie Boige, Nathalie Jacques, et al.. (2011). Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Annals of Oncology. 23(4). 919–927. 39 indexed citations

Rousseau, Frédérique, R. Bugat, Michel Ducreux, et al.. (2010). Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer: Results from the FNCLCC/GERICO 02 phase II study. Journal of Geriatric Oncology. 2(2). 105–111.

Brignone, Chrystelle, Maya Gutierrez, F. Mefti, et al.. (2010). First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. Journal of Translational Medicine. 8(1). 71–71. 202 indexed citations

Dahan, Laëtitia, Frank Bonnetain, Philippe Rougier, et al.. (2009). Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC–FFCD 9710. Endocrine Related Cancer. 16(4). 1351–1361. 68 indexed citations

10.

Conroy, Thierry, Michel Ducreux, C. Lemanski, et al.. (2009). Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): Definitive analysis of the intergroup ACCORD 03 trial. Journal of Clinical Oncology. 27(15_suppl). 4033–4033. 27 indexed citations

11.

Malka, David, Jean Mendiboure, Antoine Adenis, et al.. (2009). P.200 Monitorage des cellules endothéliales circulantes en première ligne de traitement du cancer colorectal métastatique par chimiothérapie plus bevacizumab : résultats préliminaires de l’essai de phase II randomisé FNCLCC ACCORD 13. Gastroentérologie Clinique et Biologique. 33(3). A148–A148. 1 indexed citations

12.

Bécouarn, Y., Pierre Sénesse, Simon Thézenas, et al.. (2007). A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5–FU2 + irinotecan or LV5–FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. Annals of Oncology. 18(12). 2000–2005. 11 indexed citations

13.

Alberini, Jean‐Louis, Myriam Wartski, É. Gontier, et al.. (2007). Place de l’imagerie par Tomographie par Émission de Positons pour les tumeurs stromales gastro-intestinales. Gastroentérologie Clinique et Biologique. 31(6-7). 585–593. 18 indexed citations

14.

Cvitkovic, F., Jean‐Pierre Armand, M. Tubiana-Hulin, Jean‐François Rossi, & Raymond P. Warrell. (2006). Randomized, Double-Blind, Phase II Trial of Gallium Nitrate Compared with Pamidronate for Acute Control of Cancer-Related Hypercalcemia. The Cancer Journal. 12(1). 47–53. 39 indexed citations

15.

Bennouna, Jaafar, Hervé Perrier, B Paillot, et al.. (2005). ‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’. British Journal of Cancer. 94(1). 69–73. 20 indexed citations

16.

Balaton, André, Jean‐Michel Coindre, & F. Cvitkovic. (2001). [Gastrointestinal stromal tumors].. PubMed. 25(5). 473–82. 19 indexed citations

17.

Peiffert, D., Marc Giovannini, Michel Ducreux, et al.. (2001). High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: Final results of a phase II study. Annals of Oncology. 12(3). 397–404. 68 indexed citations

18.

Bourgeois, Hugues, F. Cvitkovic, A Goupil, et al.. (1998). Association mitomycine-vinorelbine en deuxième ligne chimiothérapique dans le cancer du sein métastatique. Bulletin du Cancer. 85(9). 794–798. 3 indexed citations

19.

Peiffert, D., Jean‐François Seitz, P. Rougier, et al.. (1997). Preliminary results of a phase II study of high-dose radiation therapy and neoadjuvant plus concomitant 5-fluorouracil with CDDP chemotherapy for patients with anal canal cancer: A French cooperative study. Annals of Oncology. 8(6). 575–581. 46 indexed citations

20.

Cvitkovic, F., et al.. (1993). Pilot study of 6 weeks of chemoradiotherapy with 5 FU and hydroxyurea in malignant gliomas. Journal of Neuro-Oncology. 15(1). 9–17. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact